The Latest Breaking News from Grail

Activist investor Carl Icahn is fighting for control of Illumina after the acquisition of Grail. In response, ILMN stock surged Monday.

Illumina stock plunged to its lowest point in three months Tuesday after the gene-sequencing giant issued a disappointing outlook for 2023.

Researchers believe the main cause for surging cancer rates is because humans are living longer. A new test is hoping to detect cancerous cells to allow for earlier treatment for the disease

Illumina stock jumped Tuesday after the EC blocked its acquisition of Grail — another step in a battle over the early cancer-detection outfit.

Reuters EQT Corp Close To Buying THQ Appalachia

Wall Street Journal

One way to eliminate the competition in business is simply to buy them out and shut them down. And that means less choice for consumers and sometimes the loss of innovative and, in the case of the pharmaceutical industry, even life-saving products. But such so-called killer acquisitions are likely to…

Fresh off the Federal Trade Commission’s successful challenges to four hospital mergers, the Biden administration’s new majority on the commission is primed to more aggressively combat consolidation in the health care industry than it has in past years.

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…